Hypromellose

證據等級: L5

預測適應症: 10 個

Hypromellose: From Pharmaceutical Excipient to Hepatic Veno-Occlusive Disease-Immunodeficiency Syndrome

One-Sentence Summary

Hypromellose (HPMC) is a semi-synthetic cellulose derivative used extensively as an inactive pharmaceutical excipient — functioning as a film-coating agent, viscosity modifier, and controlled-release matrix — rather than as a therapeutic agent in its own right. The TxGNN model predicts it may be effective for Hepatic Veno-Occlusive Disease-Immunodeficiency Syndrome (VODI), an ultra-rare condition with fewer than 100 reported cases globally. There are currently no clinical trials and no published literature directly supporting this prediction, and the mechanistic basis is assessed as implausible given Hypromellose’s established pharmacological profile.

Quick Overview

Item	Content
Original Indication	No approved therapeutic indication (used as a pharmaceutical excipient)
Predicted New Indication	Hepatic Veno-Occlusive Disease-Immunodeficiency Syndrome
TxGNN Prediction Score	98.30%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Hypromellose. Based on known information, Hypromellose is a semi-synthetic cellulose ether (methylhydroxypropyl cellulose) classified as an inactive pharmaceutical excipient. Its primary roles are physical in nature: forming protective films on tablet coatings, increasing viscosity in liquid formulations, acting as a controlled-release matrix former, and functioning as a lubricant in ophthalmic preparations (artificial tears). Hypromellose has no established pharmacological activity at recognised therapeutic targets.

Hepatic veno-occlusive disease-immunodeficiency syndrome (VODI) is caused by loss-of-function mutations in the SP110 gene, producing combined defects in hepatic sinusoidal endothelial integrity and B/T-cell immune function simultaneously. Any plausible therapeutic intervention would need to address hepatic fibrosis, vascular endothelial injury, or immune reconstitution — biological activities that have not been demonstrated for Hypromellose in any preclinical or clinical setting.

While a small number of in vitro studies have noted marginal antioxidant properties for cellulose-based polymers, no translational evidence links these observations to hepatic protection or immunomodulation in vivo. The TxGNN model’s high prediction score for this indication most likely reflects a knowledge graph pattern-matching artefact rather than a genuine pharmacological signal, particularly given the ultra-rare nature of VODI (fewer than 100 cases reported globally) and the absence of any corroborating evidence across all 10 predicted indications.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top predicted indication.

Australia Market Information

Hypromellose is not registered on the Australian Register of Therapeutic Goods (ARTG) as a standalone therapeutic product. It does not hold any ARTG entries as an active ingredient. It may appear as a listed excipient within the product information of other approved therapeutic goods, but no independent therapeutic registration exists with the TGA.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Hypromellose is a pharmaceutical excipient with no established therapeutic pharmacological activity; all 10 TxGNN-predicted indications are rated L5 (model prediction only, no supporting studies), and the Evidence Pack’s own mechanistic rationale analysis consistently assesses each predicted connection as implausible or non-existent.

To proceed, the following is needed:

Verification that TxGNN’s knowledge graph is correctly classifying Hypromellose as an excipient rather than an active pharmaceutical ingredient, as high prediction scores across all indications suggest a possible data ingestion artefact
A systematic review of any peer-reviewed preclinical evidence demonstrating genuine pharmacological activity (e.g. immunomodulatory, hepatoprotective, or anti-fibrotic) for Hypromellose or its cellulose-derivative analogues
If any pharmacological activity is identified in the literature, a mechanistic plausibility assessment against the VODI disease pathway (SP110 mutation → combined hepatic and immune failure)
If evidence emerges to support further investigation, a full TGA regulatory pathway assessment and appropriate safety profiling before any clinical consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.